Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geographyMélanie Deschasaux, Max Nieuwdorp, Kristien E. Bouter et al.|Nature Medicine|2018Cited by 745
Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trialPieter F. de Groot, Max Nieuwdorp, Silvia Pellegrini et al.|Gut|2020Cited by 305
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical studyAnnemarie B. van der Aart‐van der Beek, Hiddo J.L. Heerspink, Ellen M. Apperloo et al.|Diabetes Obesity and Metabolism|2023Cited by 28
GLP-1-based therapeutics for cardiorenal protection in metabolic diseasesEllen M. Apperloo, Marcel H.A. Muskiet, Hiddo J.L. Heerspink et al.|Nephrology Dialysis Transplantation|2025Cited by 9
Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover TrialEllen M. Apperloo, Marcel H.A. Muskiet, Annemarie B. van der Aart et al.|Diabetes Care|2025Cited by 3